Stay updated with breaking news from Jonathan Bromberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AUSTIN, Texas, April 11, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant rejection. The published manuscript can be found here.
Record Number of 65 Abstracts Showcasing CareDx Innovation Including Data Showing Clinical Utility of AlloSure Kidney to Guide Immunosuppression Management Experts Review Advancements in... | June 1, 2023
Published: Jun 04, 2021 Transplant physicians to present 40 scientific abstracts, plus two symposia to highlight latest data from multi-center studies on clinical utility of AlloSure SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its participation in the 2021 American Transplant Congress (ATC), including two symposia and the presen...
GuruFocus Article or News written by Marketwired and the topic is about:
Published: Apr 05, 2021 SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its presence at the National Kidney Foundation’s 2021 Spring Clinical Meetings, which will take place virtually, April 6-10, 2021. As a leader in non-invasive approaches for assessing the health of transplanted kidneys, CareDx will host “Next Generation Ca...